FDA Seeks Feedback on Surrogate Endpoint Table

November 2, 2018

On December 13, 2016, the 21st Century Cures Act was signed into law with the intention of speeding FDA’s approval time for drugs and medical devices.  When signed, the Cures Act increased FDA’s authority in a variety of areas.  It also created a number of new mandates that the Agency is required to comply with, one of which mandated FDA to “publish a list of surrogate endpoints (SEs) used as a basis to approve or license a drug or biological product under both accelerated and traditional approval provisions.”  The list, which was published on July 25, 2018, “fulfills the legislative requirement and is intended to provide valuable information for drug developers on endpoints that may be considered and discussed with FDA for individual development programs.”

The table includes:

  • SEs that sponsors have used as primary efficacy clinical trial endpoints for NDA or BLA approvals
  • SEs that may be appropriate for use as a primary efficacy clinical trial endpoint for drug or biologic approval (although the SEs have not necessarily been used to support and approved NDA or BLA)

FDA believes the table “should facilitate discussions of potential SEs by sponsors when developers are designing their drug development programs.”  In addition to the SE table, the FDA’s accompanying webpage also explains the purpose of the table and provides additional background information.

On Tuesday, October 30th FDA published a notice in the Federal Register seeking comments and suggestions from the public.  The Agency plans to use the feedback to:

  • Help determine the utility of the SE table
  • Develop future iterations of the SE table
  • Identify the best methods for conveying information on the Agency’s website

The Agency is asking that all interested parties submit written and electronic comments by December 31, 2018.

Are you in the process of preparing an NDA or BLA for submission to the FDA?  This SE table could assist with the development of your application.  We can help you develop and submit your application to the FDA, helping you maximize your chance of success with the Agency.  Contact us today to learn more about our services and how we can help you.


November 11, 2015

There’s an App for That: FDA Launches Orange Book Express App

On November 9, 2015, FDA launched the Orange Book Express application, which provides a list of the drug products approved by the FDA. What is the Orange Book? The Drug Price Competition and Patent...

September 6, 2016

FDA Approves Erelzi™, the Third US Biosimilar Product

On Wednesday, August 30th, the FDA announced the approval of Sandoz’s Erelzi™ (etanercept-szzs). Erelzi is biosimilar to Amgen’s Enbrel® (etanercept) and is indicated for the treatment of multiple...

April 7, 2016

FDA Approves Inflectra™, the Second US Biosimilar

On Tuesday, April 5th, FDA announced the approval of Inflectra™ (infliximab-dyyb), a biosimilar version of Janssen Biotech's Remicade® (infliximab), for a number of indications. Inflectra is...